Liquidity - Additional Information (Detail) - USD ($)			1 Months Ended	3 Months Ended		12 Months Ended
	May 09, 2024	Oct. 02, 2023	Mar. 31, 2022	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2022	Dec. 31, 2024	Jul. 19, 2024
Cash And Cash Equivalents [Line Items]
Net loss				$ (43,773,000)	$ (21,398,000)
Accumulated deficit				(496,033,000)			$ (452,260,000)
Cash and cash equivalents				81,331,000			87,928,000
Marketable securities current				208,619,000			$ 203,509,000
Principal amount of term loans				50,000,000
Net cash used in operating activities				(32,752,000)	(12,528,000)
Proceeds from exercise of common stock warrants				3,011,000	$ 923,000
Securities Purchase Agreement [Member]
Cash And Cash Equivalents [Line Items]
Sale and issuance of warrants				10,000,000
Proceeds from exercise of common stock warrants				47,800,000
Warrants aggregate exercise price				2,200,000
Jefferies LLC [Member] | Maximum [Member]
Cash And Cash Equivalents [Line Items]
Aggregrate Offering Price								$ 150,000,000
Loan And Security Agreement [Member] | Oxford [Member]
Cash And Cash Equivalents [Line Items]
Principal amount of term loans				$ 50,000,000
Debt instrument term				60 months
Debt Instrument Maturity Extension Period				12 months
Debt instrument interest period				48 months
Debt Instrument interest rate stated percentage				5.50%
Debt instrument date of first required payment				Feb. 01, 2029
Debt instrument date of final required payment				Dec. 01, 2029
Loan And Security Agreement [Member] | Oxford [Member] | FDA Approval OF VYKATXR Tranche one [Member]
Cash And Cash Equivalents [Line Items]
Debt instrument additional borrowing amount				$ 50,000,000
Debt instrument date of final borrowings				Sep. 30, 2025
Loan And Security Agreement [Member] | Oxford [Member] | FDA Approval OF VYKATXR Tranche Two [Member]
Cash And Cash Equivalents [Line Items]
Debt instrument additional borrowing amount				$ 25,000,000
Debt instrument date of first borrowings				Oct. 01, 2025
Debt instrument date of final borrowings				Sep. 30, 2026
Loan And Security Agreement [Member] | Oxford [Member] | Contingent upon certain commercial milestones [Member]
Cash And Cash Equivalents [Line Items]
Debt instrument additional borrowing amount				$ 25,000,000
Loan And Security Agreement [Member] | Oxford [Member] | Mutual Consent of Soleno and Oxford [Member]
Cash And Cash Equivalents [Line Items]
Debt instrument additional borrowing amount				$ 50,000,000
Underwritten Public Offering [Member]
Cash And Cash Equivalents [Line Items]
Issuance of common stock (shares)	3,450,000	3,450,000	2,666,667
Proceeds from offering after deducting underwriting discount and other estimated offering expenses	$ 158,700,000	$ 69,000,000	$ 13,800,000
Underwriter discount and other offering expenses	$ 9,700,000
Price per unit	$ 46	$ 20.00	$ 3.75
Underwritten Public Offering [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Cash And Cash Equivalents [Line Items]
Proceeds from sale of common stock, net of costs						$ 60,000,000